Raymond James Initiates Coverage on Benitec Biopharma

Raymond James has initiated coverage on Benitec Biopharma Inc. (BNTC), assigning the stock an Outperform rating with a price target of $14 per share. This marks the firm's first formal research position on the biotechnology company's market outlook.